Home > Resources > Whitepapers > Cell Cultivation without Contamination

Cell Cultivation without Contamination

Sponsored

No other problem in cell culturing is as universal as microbial contamination. In order to avoidit, good sterile techniques and thorough culture handling are essential. Beyond that, the CO2 incubator plays a key role because it provides optimal growth conditions not only for cell cultures but also for various unwanted microbes.

Spotlight

Falck UK

Falck is the UK’s leading provider of Patient Transport. Operating from 7 regional headquarters nationwide, we offer a range of patient transport services including non-emergency, high dependency, renal, bariatric, urgent care and paediatric retrieval as well as A&E and front line response through our Emergency Ambulance Division. Falck in the UK is a subsidiary of the Falck Group, the global leader in emergency and ambulance services. Present across 44 countries on six continents and operating more than 2500 ambulances, Falck has the world’s largest international ambulance fleet.

OTHER WHITEPAPERS

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

Read More

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

whitePaper | August 24, 2022

The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).

Read More

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

Read More

Effective solutions for global challenges

whitePaper | April 24, 2023

Despite challenging global conditions, the Swiss biotech industry was able to raise more than CHF 1.33 billion in 2022, with roughly CHF 0.78 billion collected by public companies and the remaining CHF 0.55 billion collected by private companies.

Read More

Lentivirus production study in the scale-X™ fixed-bed bioreactor

whitePaper | April 24, 2023

Implementation of a metabolite-based cell density<br /> estimation and evaluation of harvest strategies for<br /> Lentivirus production with HEK293T cells

Read More

2022 Biosimilars Report: The U.S. Journey and Path Ahead

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

Read More

How advanced purification technologies are speeding the hunt for new protections against disease

whitePaper | November 24, 2022

Smallpox was the first infectious disease for which an effective vaccine was developed. In the late 1700s, British doctor Edward Jenner devised a method to inoculate people with cowpox pus to give them immunity against smallpox, a much more deadly disease.

Read More

Use of PS-DVB Columns and Matched Buffers in the Purification and Scale-Up of mRNA Drug Candidates

whitePaper | August 24, 2022

The validity of mRNA as an approved pharmaceutical is now largely accepted, with the historic launch and administration of billions of doses of mRNA Covid vaccines (1).

Read More

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

Read More

Effective solutions for global challenges

whitePaper | April 24, 2023

Despite challenging global conditions, the Swiss biotech industry was able to raise more than CHF 1.33 billion in 2022, with roughly CHF 0.78 billion collected by public companies and the remaining CHF 0.55 billion collected by private companies.

Read More

Lentivirus production study in the scale-X™ fixed-bed bioreactor

whitePaper | April 24, 2023

Implementation of a metabolite-based cell density<br /> estimation and evaluation of harvest strategies for<br /> Lentivirus production with HEK293T cells

Read More

2022 Biosimilars Report: The U.S. Journey and Path Ahead

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

Read More

More Whitepapers

Spotlight

Falck UK

Falck is the UK’s leading provider of Patient Transport. Operating from 7 regional headquarters nationwide, we offer a range of patient transport services including non-emergency, high dependency, renal, bariatric, urgent care and paediatric retrieval as well as A&E and front line response through our Emergency Ambulance Division. Falck in the UK is a subsidiary of the Falck Group, the global leader in emergency and ambulance services. Present across 44 countries on six continents and operating more than 2500 ambulances, Falck has the world’s largest international ambulance fleet.

Events